01
Commercial
Nouscom’s NOUS-209 viral vector neoantigen vaccine earns FDA Fast Track for Lynch Syndrome cancer prevention - AllSci
Nouscom, a clinical-stage biotech headquartered in Basel, Switzerland, announced receipt of US FDA Fast Track Designation for NOUS-209, a viral vector-based, off-the-shelf neoantigen cancer vaccine, for the prevention of Lynch Syndrome (LS)-associated cancers in carriers with gen…